Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INTELLANCE-2: ABT-414 Alone or ABT-414 Plus Temozolomide Versus Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group

Trial Profile

INTELLANCE-2: ABT-414 Alone or ABT-414 Plus Temozolomide Versus Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Depatuxizumab mafodotin (Primary) ; Lomustine; Temozolomide
  • Indications Anaplastic astrocytoma; Diffuse intrinsic pontine glioma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms INTELLANCE 2
  • Sponsors AbbVie; AbbVie Germany
  • Most Recent Events

    • 15 Feb 2021 Results of a pre-specified exploratory analysis assessing the health-related quality of life (HRQoL) and neurological deterioration-free survival (NDFS), published in the European Journal of Cancer
    • 23 May 2020 This trial is completed in Poland (Global End Date: 24 Jun 2019), according to European Clinical Trials Database record.
    • 08 May 2020 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top